Robert Motzer, MD, and Elizabeth Plimack, MD, discuss clinical findings in the treatment of advanced RCC from the recent KCRS 2023 meeting, emphasizing the significance of circulating tumor cells, advances in imaging, and the potential of adjuvant therapies, particularly pembrolizumab.
Related Keywords
Elizabeth Plimack , Robert Motzer , , Evolving Treatments , Advanced Renal Cell Carcinoma , Renal Cell Carcinoma , Metastatic Renal Cell Cancer , Pembrolizumab , Lenvatinib , Dose Reduction , Adjuvant Therapy , Toxicity Management , Hypertension , Blood Pressure , Thyroid Toxicity , Proteinuria , Liver Toxicity , Hand Foot Syndrome , Fatigue ,
comparemela.com © 2020. All Rights Reserved.